NCT06116630 StrokeCog-BBB to Study Cognitive Outcomes Following Stroke
| NCT ID | NCT06116630 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2022-05-17 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2022-05-17 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about cognitive outcomes in stroke patients. The main question it aims to answer are: 1. Is blood-brain barrier permeability compromised for years after stroke, 2. Is a blood biomarker of imbalanced angiogenesis dysregulated in chronic stroke and 3. Are there biomarkers that separately or together predicts cognitive decline after stroke, and are other MRI, blood, and clinical characteristics that are associated. Participants will undergo cognitive testing and MRIs two years apart. Researchers will compare cognitive outcomes in non-stroke patients who have cardiovascular risk factors to understand the effects of stroke on these outcomes.
Eligibility Criteria
Inclusion Criteria: * Aged 45 years or over * One or more vascular risk factors (e.g. high blood pressure, diabetes or vascular disease such as angina, a previous heart attack, a heart bypass or peripheral artery disease in the legs) * Established vascular disease (previous MI, angina, vascular stent in the peripheral bed) * Sufficiently fluent in written and spoken English * Living independently in the community * Willing/able to give consent to study participation. Exclusion Criteria: * Current treatment with IL-1 blockade or established immune-suppressant therapy (e.g. IL-1Ra or IL-1 antibodies), or treatment within the last 3 months * Currently participating in a clinical trial of investigation medicinal product (CTIMP) or device trial. * No history of any previous ischaemic or haemorrhagic stroke, a mini-stroke or a serious brain injury * Do not have dementia * Renovascular Disease * Major neurological disease (immune mediated, previous brain tumors)
Contact & Investigator
Marion Buckwalter, MD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT06116630 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 90 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06116630 currently recruiting?
Yes, NCT06116630 is actively recruiting participants. Contact the research team at musabbir@stanford.edu for enrollment information.
Where is the NCT06116630 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT06116630 clinical trial?
NCT06116630 is sponsored by Stanford University. The principal investigator is Marion Buckwalter, MD at Stanford University. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.